Parallel Bio的动态

Reminder! Register now for today's Fierce webinar on leveraging EHR and WGS data to accelerate drug discovery. Join at 4 PM BST / 5 PM CET to explore the latest insights in this exciting field. #DrugDiscovery #Genomics #FierceWebinar

Before starting with #BIO2024, I am thrilled to tell everyone that I just gave a short speech for presenting what Vacino Biotech is doing on the Newsweek: The New Era of Life Science, an affliate event to BIO 2024. Thanks to Newsweek Amit’ introduction. After on the shortlist of Vaccine Industry Excellent (Vie), WWCDC 2024, our Vacino’s oral COVID-19 epitope vaccine, Vacino-CO, has an important time to stop future Disease X pandemic. Another Vacino’s developing drug is miRNA-based Alzheimer’s disease drug. It can prevent the damage from excess neuroinflammation caused by microglia cells through up-regulation of neuron’s PD-L1 level. It is also expected to treat neuroinflammation-related disease such as Parkinson’s disease etc. The final is Vacino’s brain delivery technology. With this technology, it’s not a dream to deliver large drug molecules and can be manufactured as many different drug modalities. Don’t hesitate, quickly reach out to us. #VacinoBiotech #Newsweek #BIOaffiliateevent #Vacino_CO #Vacino_ADmir #Vacino_BT #NewEraOfLifeScience

Aptamer Group PLC (AIM:APTA) shares rose 10% as it said proof-of-concept work on its new drug-targeting agent Optimer+ produced highly specific binders with significantly higher affinity than current technology platforms. Development times for Optimer+ were?also significantly faster than existing aptamer-based approaches, said the statement. Preliminary experiments in mice also indicated Optimer+ binders to be well tolerated and demonstrate the basic requirements for therapeutic applications. Aptamer added it expects the new?Optimer+?platform to expand the capability of its binders in all applications, especially in precision medicine.? Arron Tolley, Aptamer’s chief technical officer, said; “Both the lab-based research and the initial animal experiments suggest that Optimer+ will be well placed to deliver the next generation of binders to enable the targeted delivery of precision medicines. More at #Proactive #ProactiveInvestors #AIM #APTA https://ow.ly/RZP6105jSNT

?? In our first episode of 2024, we had the incredible opportunity to dive deep into the world of immunology and T-cell therapy with two distinguished guests from Virax Biolabs - CEO James Foster and COO Nigel McCracken. ?? James Foster, a visionary leader and co-founder of Virax Biolabs, shared his fascinating journey from finance to biotech. He discussed the company's mission to revolutionize immune profiling with their cutting-edge "Viru Immune" platform, aiming to tackle the growing challenges of post-viral syndromes and chronic inflammation. ?? Nigel McCracken, with his extensive experience, shed light on the operational complexities and strategic growth of Virax. His insights on the development of companion diagnostics are a must-hear for anyone interested in the future of personalized medicine. ?? Key Takeaways: The importance of early detection in disease management. The role of innovation and execution in scaling biotech ventures. The growing need for effective diagnostics in the face of long COVID and chronic conditions. ?? Join us in this enlightening conversation and discover how Virax Biolabs is shaping the future of healthcare. Don't forget to share your thoughts and insights in the comments below! #LifeScienceSuccess #ViraxBiolabs #Immunology #BiotechInnovation #HealthcareFuture #TCellTherapy #PodcastHighlight #LeadershipInsights #PersonalizedMedicine #BiotechCommunity

Thank you Elizabeth Eaton for this wonderful article covering Rubedo Series A!

Human tissue testing is advancing drug discovery by bridging the gap between animal models and clinical trials. This translational approach allows us to better predict human responses early in development, enhancing the clinical relevance of preclinical data and supporting more informed decision-making. Integrating human tissue studies is helping us bring more precise, impactful treatments closer to patients. Find out more here: https://hubs.li/Q02WXzrs0 #DrugDiscovery #ClinicalResearch

What's our data used for? ?? "The data we supply gives further confidence for decision making and reduces the risks in drug discovery." The data we supply is often part of drug development programmes which when taken forward will also form part of FDA /EMA regulatory applications. On some occasions, our models are used before preclinical animal studies to refine the number of leads. On other occasions, animal studies have already been performed and the aim is to validate the results in complex in vitro models of human tissue. Dr Carolina Gandara, Head of retina assay development answers our questions: https://lnkd.in/eYVqJEP6 #Retina #Data #DrugDiscovery

Rubedo Life Sciences has spent the last six years meticulously laying the groundwork for its pipeline of senescent cell-targeting treatments -- a field that grabbed headlines in the late 2010s for its anti-aging potential. "We didn't want to rush, we wanted to make sure that we were solid before embarking into clinical development. And now we are ready," CEO Marco Quarta told me. Now, flush with a $40-million series A, the biotech plans to enter the clinic this year with its lead senolytic to treat atopic dermatitis and psoriasis: diseases with unmet patient need, carefully selected as the best to demonstrate clinical proof-of-concept. For more on how Rubedo has navigated the senescent cell space, read here: https://lnkd.in/g23Ens2h

That is great news (and somewhat overdue). As an academic clinician, I hope this FDA-Innovation Hub will look beyond the typical FDA/CBER/CDER missions and pay (a lot more) attention to two main bottlenecks in bringing advanced therapeutics to patients with rare diseases: ? 1] A contracting workforce of (academic) physicians that are, and will be (see ASGCT report), tasked with implementing these rare therapeutics.? ? https://lnkd.in/ehi8e79b ? https://lnkd.in/e-FbPgDu ? https://lnkd.in/eUP3Ez3j ? ? 2] General lack of implementation strategies by Sponsors (the “what happens now that the product is FDA-approved”). The FDA-Innovation Hub can help with harmonizing implementation strategies, encouraging Sponsors to share implementation plans with the FDA (before approval) and potential treatment centers, related, harmonized certification criteria for QTCs. Last, but not least, this FDA-Innovation Hub should play a greater role in the determination of value (and the payer side of the therapeutic supply chain). ?

Imagine a compound ?? that takes a sick mouse ?? and turns it into a happy ??, healthy one. Sounds promising, right? But there's a critical distinction to make: a compound that treats a condition in an animal is not yet a drug. The real challenge lies in translating that success into humans. One of the biggest hurdles in Drug R&D is this very translation from animal (and other in-vitro and in-vivo) models to human trials. Just because something works in animals does not mean it will work in humans. Understanding the biological differences between animals and humans is crucial to overcoming this challenge. While we do share a significant portion of our genome with animals used in preclinical testing—like mice, rats, and of course, primates—the differences are profound enough to create major obstacles when moving from the preclinical to the clinical stages of drug development. It's estimated that over 85% of drugs that enter clinical trials fail, despite showing promising results in preclinical models (Arrowsmith, 2011; Hay et al., 2014). Translation is tough, and that's where much of the risk and complexity in drug development lies. ______________________ Love ?? this post? Add your comments ??, re-share ? it with your network, follow me ?? for more posts like this, and DM me ?? if you want to deep dive on this topic!**